Novartis acquires UK biotech Myricx Bio for up to $1.5B, gaining a novel NMTi ADC payload platform and two lead assets targeting B7-H3 and HER2. The deal includes $1.1B upfront with $400M in milestones, expected to close in H2 2026.
iPSC-derived NK cell therapies are advancing rapidly with 12+ companies developing 15+ pipeline drugs. Japan's PMDA approved an iPS cell-derived NK cell therapy for mediastinal germ cell tumors in December 2025. Key clinical milestones include Century Therapeutics' CNTY-101 continuing in a Phase I/II trial.
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
The FDA has granted Fast Track designation to PLT012, a first-in-class anti-CD36 monoclonal antibody for hepatocellular carcinoma treatment. The Phase 1 trial is currently enrolling patients in Texas.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
Trethera Corporation completed Phase 1 solid tumor dose escalation trial for TRE-515 and received FDA Fast Track designation for prostate cancer and Orphan Drug status for two autoimmune neurologic diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07612137 |
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07606612 |
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07589205 |
Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT07570563 |
Clinical Study of the Safety and Efficacy of QH101 Cell in Patients With Malignant Tumors. |
RECRUITING | PHASE1/PHASE2 |
| NCT07556276 |
Study of CMTS1215 Injection in Patients With Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07554196 |
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors |
COMPLETED | PHASE1 |
| NCT07545486 |
Ablative Therapy of Oligometastatic Tumor After Response to Conventional First Line Treatment |
NOT_YET_RECRUITING | |
| NCT07541573 |
GTB-5550 in Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07532018 |
DXP-106 in Solid Tumor Patients. |
RECRUITING | PHASE1 |
| NCT07517198 |
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors |
RECRUITING | PHASE1 |
